Nectar Lifescience Ltd

  • BSE Code : 532649
  • NSE Symbol : NECLIFE
  • ISIN : INE023H01027
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 10.04 0.28(2.87%)

Open Price ()

9.99

Prev. Close ()

9.76

Volume (No’s)

596,752

Market Cap ()

195.04

Low Price ()

9.71

High Price ()

10.23

 

Book Closure

From Date To Date Announcement
02-Mar-2026 NA Updation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026. We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on Monday, March 02, 2026, have, inter-alia, noted, decided and approved the following matters: 1. To acquire 100% paid- up equity share capital of Avensis Exports Private Limited ('AEPL'). 2. Change in Registrar and Share Transfer Agent ('RTA') of the Company from M/s. KFin Technologies Limited ('KFIN') to M/s. Alankit Assignments Limited ('AAL'). We would like to inform you that the Board of the Company at its meeting held on 02.03.2026 has considered and approved the acquisition of 100% paid-up equity share capital of Avensis Exports Private Limited. (As Per BSE Announcement Dated on 02.03.2026)
28-Feb-2026 01-Mar-2026 Outcome Of Board Meeting. The Notice is also available on the website of the Company i.e. www.neclife.com/about-3-9 and website of KFin Technologies Limited at https://evoting.kfintech.com. Members whose names appeared in the Register of Members/ List of Beneficial Owners as on the cut-off date i.e. Friday January 23 2026 are eligible for the purpose of remote e-voting. The remote e-voting period shall commence on Friday January 30 2026 09:00 A.M (IST) and will end on Saturday February 28 2026 05:00 P.M. (IST). The results of the Postal Ballot will be announced on or before March 02 2026. Nectar Lifesciences Limited has informed the Exchange regarding Results of Postal Ballot (As Per BSE Announcement Dated on: 01/03/2026)
23-Jan-2026 NA Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended on December 31 2025 and matters related thereto and other business matters if any. Please find attached herewith Results For Quarter And Nine months Ended December 31, 2025. We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on Friday, January 23, 2026, have, inter-alia, noted, decided and approved the following matters: 1. Approved the adoption of new set of Memorandum of Association ('MOA') with amended object clause. 2. Appointment of Internal Auditor for the financial year 2025-26 and 2026-27. 3. To seek approval of shareholders through postal ballot process for adoption of new set of MOA with amended object clause of the Company. In accordance with the applicable laws and circulars thereunder, the Notice will be sent in electronic mode only to those members whose names appeared in the Register of Members/ List of Beneficial Owners maintained by the Company/ Depositories respectively as at close of business hours on Friday, January 23, 2026 ('Cut-off date'). (As per BSE Announcement dated on: 23.01.2026)
31-Dec-2025 06-Jan-2026 Board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on December 03, 2025, has considered and approved the following matters: 1. The buyback of equity shares. The buyback equity shares for an amount of INR 81,00,00,000/- (Indian Rupees Eighty-one crore only) ('Buyback Size') at a price of INR 27/- (Indian Rupees Twenty- seven only) per equity share ('Buyback Price'), payable in cash, comprising of a purchase of 3,00,00,000 (Three crore only) fully paid up equity shares of the Company of face value of INR 1/- (Indian Rupee one only) each ('Equity Shares') representing up to 13.38% of the total number of Equity Shares in the existing total paid-up Equity Share capital of the Company, from the equity shareholders of the Company as on a record date. The buyback Size does not exceed 10% (ten per cent) of the total paid-up equity capital and free reserves of the Company (on a standalone and consolidated basis) based on audited financial statements of the Company for the year ended on March 31, 2025. The buy back is proposed to be made from all equity shareholders of the Company excluding Promoters, members of Promoter Group, as on the record date on a proportionate basis through the 'Tender Offer' route in accordance and consonance with the provisions contained in the Companies Act, 2013 ('Act') and the SEBI (Buy Back of Securities) Regulations, 2018 ('Buyback Regulations') (including any statutory modification(s) or re-enactment of the Act or Buyback Regulations) and Rules made or circular issued thereunder. The buyback size does not include any expenses or transaction costs incurred or to be incurred for the buyback, such as, brokerage, filing fees, advisory fees, intermediaries' fees, public announcement publication expenses, printing and dispatch expenses, applicable taxes such as securities transaction tax, goods and services tax, stamp duty etc. and other incidental and related expenses. Source : Business Standard Date 05.12.2025 Please find enclosed herewith Corrigendum for Public Announcement in relation to Buyback of equity shares of the Company (As per BSE Announcement dated on: 10.12.2025) Trading Members of the Exchange are hereby informed that, NECTAR LIFESCIENCES LIMITED has fixed Record Date for the purpose of determining the entitlement and Names of the Shareholders, who are eligible to participate in the buyback offer :- DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE NECTAR LIFESCIENCES LIMITED (532649) RECORD DATE 24/12/2025 PURPOSE To determine the entitlement and Names of the Equity Shareholders, who are eligible to participate in the buyback offer. Ex-Entitlement basis from Date & Sett. No. 24/12/2025 DR- 784/2025-2026 Trading Members of the Exchange are requested to take note of it. (As Per BSE Notice Dated on 22.12.2025) Please find enclosed letter of offer for Buyback of equity shares of the Company (As per BSE Announcement dated on: 29.12.2025) Newspaper Publication of post Buyback Public Announcement (As per BSE Announcement dated on: 15.01.2026) Master Capital Services Ltd ('Manager to the Buyback') has submitted to BSE a copy of Post Buyback Public Announcement for the attention of equity shareholders / beneficial owners of equity shares of Nectar Lifesciences Ltd (the 'Company'). Read less.. (As Per BSE Announcement Dated on 16.01.2026) Please find attached herewith the letter of Completion of extinguishment of equity shares of the Company (As Per BSE Announcement Dated on 21.01.2026)
24-Dec-2025 NA Buy Back of Shares

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew